These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3118551)

  • 1. Comparison of single agent cisplatin and cisplatin containing combinations in treatment of murine bladder cancer.
    Hickey DP; Brausi M; Blatnik AF; Soloway MS
    Urology; 1987 Nov; 30(5):484-7. PubMed ID: 3118551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer.
    Brausi M; Blatnik A; Soloway MS
    Urology; 1990 Mar; 35(3):253-6. PubMed ID: 2316090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
    Miller RS; Torti FM
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder cancer chemotherapy: is response of squamous tumours different to that of transitional cell tumours?
    Oliver RT
    Ann Oncol; 1991 Feb; 2(2):87-8. PubMed ID: 1711366
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic chemotherapy of murine bladder cancer.
    Soloway MS; Niell HB; Matheny RB; Blatnik A
    Urology; 1984 Apr; 23(4 Suppl):129-34. PubMed ID: 6538713
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
    J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single and sequential combination intravesical chemotherapy of murine bladder cancer.
    Soloway MS; Nissenkorn I; McCallum LW; Murphy WM
    Urology; 1982 Feb; 19(2):169-75. PubMed ID: 6800090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for advanced urothelial cancer.
    Yagoda A
    Semin Urol; 1983 Feb; 1(1):60-74. PubMed ID: 6382528
    [No Abstract]   [Full Text] [Related]  

  • 9. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.
    Koch MO; Coussens D
    Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122
    [No Abstract]   [Full Text] [Related]  

  • 11. M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Watson RC; Hollander PS; Fair WR
    Prog Clin Biol Res; 1988; 260():481-5. PubMed ID: 3283768
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy for invasive bladder carcinoma.
    Fair WR
    Mayo Clin Proc; 1988 Jan; 63(1):86-7. PubMed ID: 3275847
    [No Abstract]   [Full Text] [Related]  

  • 13. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of urothelial tract tumors.
    Yagoda A
    Cancer; 1987 Aug; 60(3 Suppl):574-85. PubMed ID: 3297286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Systemic chemotherapy in advanced bladder cancer. New aspects].
    Jakse G
    Wien Klin Wochenschr; 1987 Jan; 99(2):54-7. PubMed ID: 3564487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder.
    Miller RJ; Bahnson RR; Banner B; Ernstoff MS; O'Donnell WF
    Cancer; 1990 Jan; 65(2):207-10. PubMed ID: 2295043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of M-VAC combination chemotherapy in the treatment of patients with invasive and metastatic bladder cancer.
    Soloway MS
    Eur Urol; 1988; 14 Suppl 1():42. PubMed ID: 3181242
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemotherapy and bladder cancer.
    Garnick MB
    J Urol; 1989 Jan; 141(1):107. PubMed ID: 2642307
    [No Abstract]   [Full Text] [Related]  

  • 19. The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study.
    Meyers FJ; Palmer JM; Freiha FS; Harker EG; Shortliffe LD; Hannigan J; McWhirter K; Torti FM
    J Urol; 1985 Dec; 134(6):1118-21. PubMed ID: 3903223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract.
    Akaza H; Kotake T; Miyanaga N; Koiso K
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):70-4. PubMed ID: 7512280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.